Fill–Finish & Aseptic Drug Product

Design → GMP, without detours

Dual hubs: San Diego, CA (Southern California) & Montréal, Canada
Scope: Sterile filtration and aseptic filling for vials, prefilled syringes (PFS), and cartridges; isolator/RABS operations; formulation and hold-time readiness; visual inspection (manual/automated); container-closure integrity (CCIT); lyophilization (cycle design through validation); packaging, labeling, and cold chain to clinic.

At MycoVista, fill–finish is where science becomes medicine. It is also where quality failures are least forgiving. Therefore, we design drug product (DP) as an integral extension of drug substance (DS), not as an afterthought. From the first technical discussion, we translate your QTPP → CQAs → CPPs into a manufacturing playbook that our operators can run at 3 a.m. under inspection. We prefer headroom over hero runs, closed processing where it earns its keep, and documents that stand up when regulators ask “show me.”

Why teams choose MycoVista for fill–finish

Decisive. Technical. Audit-ready. That’s our operating system.

End-to-end ownership. Formulation refinement → bulk prep → sterile filtration feasibility → aseptic filling (vial/PFS/cartridge) → lyophilization (if indicated) → visual inspection → CCIT → labeling/packaging → cold chain, harmonized across a unified digital QMS (ALCOA+) in two synchronized facilities.
Designed with DS reality. We inherit analytics and stability from upstream/DSP and extend them—so your DP control strategy reads like one coherent story.
Isolator-first mindset. We privilege isolators for patient risk reduction and operator safety, with RABS where justified by program needs.
Evidence over optimism. Filter recovery, particulate risk, headspace oxygen, residual moisture, and sterility are measured, trended, and gated—never assumed.

What “Fill–Finish” means at MycoVista (scope & positioning)

We cover the DP continuum—early development through clinical and, for qualified programs, commercial-intent campaigns.

Aseptic filtration & filling of solutions and suspensions for biologics, enzymes, vectors, and LNPs.
Lyophilized products (proteins, mAbs, select enzymes, and niche nucleic-acid presentations) including full cycle development and scale-down/scale-up models.
Presentations: glass vials (2R–50R), prefilled syringes (staked needle & luer-lock), pen/cartridge systems for device programs.
Inspection: 100% visual (manual or automated) with AQL lot qualification and defect libraries; subvisible particulate controls aligned to route.
Integrity: deterministic and probabilistic CCIT methods fit to phase and container.
Cold chain & logistics: label/pack/ship engineered to your stability truth, not theater.

Bias: the simplest DP that protects potency, ensures sterility, and survives operations—without ornamental complexity.

From QTPP to line settings (the control strategy in practice)

We reverse-engineer unit operations from patient and regulatory requirements.

QTPP—dose, route (IV/IM/SC), presentation (vial/PFS/cartridge), target shelf life, storage (2–8 °C, −20 °C, ≤−60 °C), allowable particulates, acceptable osmolality/pH, and reconstitution/in-use expectations.
CQAs—potency, sterility, endotoxin, visible/subvisible particulates, pH, osmolality, fill volume accuracy, headspace oxygen (for sensitive products), residual moisture (for lyo), appearance, and container-closure integrity.
CPPs—mixing/hold parameters, sterile filtration ΔP and temperature, line speed and dosing system (peristaltic vs piston), stopper/vacuum setpoints, environmental classification/EM limits, lyo shelf temperatures and pressures, capping forces, and inspection sensitivities.

Deliverable: a DP control strategy that ties each CQA to an operation, an assay, and a document (SOP/protocol/report) you can show an auditor.

Formulation & bulk prep (make the liquid behave)

Drug product success starts before the filling needles descend. Consequently, we first align formulation and bulk handling with what your molecule—or particle—will tolerate.

Buffer and excipients. We select pH and ionic strength for comfort and stability; we add tonicity agents, antioxidants, and surfactants only where they reduce real risk (aggregation, surface adsorption, agitation).
Device compatibility. For PFS, we consider silicone oil, tungsten, and glide-force realities; for vials, we match stopper compatibility and minimize headspace oxygen when oxidation matters.
Mixing & holds. We define shear envelopes, temperature windows, and gentle recirculation rules; we validate hold times so production doesn’t improvise.
Bioburden control. We sanitize contact paths, qualify filters, and pre-assemble single-use manifolds; we plan pre-use/post-sterilization integrity tests where required.

Transition: only when the bulk behaves on the bench do we let it near the filling needles.

Sterile filtration (feasible, recoverable, repeatable)

Filtration should remove risk, not potency. Hence we make it prove itself.

Feasibility first. We screen membrane chemistries and pore structures for recovery and throughput on real bulk, not a lab buffer look-alike.
Prefilter logic. When particulates or viscosity demand it, we stage prefilters to protect the final sterilizing grade filter without smothering the product.
Integrity tests. We employ pre- and post-run integrity testing; where applicable, we perform pre-use/post-sterilization integrity testing consistent with prevailing expectations.
Thermal & pressure discipline. We control product temperature and transmembrane pressure to avoid aggregation or shear-driven loss.

Outcome: a validated filtration recipe with yield and integrity that operators can run reliably.

Aseptic filling (vials, PFS, cartridges)

We fill under isolators by default when risk justifies it, with RABS as a deliberate choice—not a convenience.

Dosing systems. We select peristaltic for gentle handling and flexibility, piston for high precision with low viscosity drips; we verify mass/volume performance statistically.
Line controls. We set line speeds, nozzle depths, and nitrogen overlays where oxidation is a concern; we calibrate load cells and in-process check-weighers; we validate vacuum/stoppering curves.
Stoppering & capping. We tune forces to preserve integrity without stopper damage; we document torque and crimp windows operators can hold.
In-process samples. We structure sampling that maps the fill, not just the endpoints—so trends illuminate drift before it becomes deviation.

People and place: operators qualify for interventions; environmental monitoring captures viable/non-viable profiles throughout the run.

Lyophilization (when a cake beats a liquid)

Lyophilization can turn a fragile protein into a robust product—if the cycle respects physics and the protein’s temperament.

Cycle design. We identify collapse and eutectic points, then we set freezing ramps, annealing steps when needed, and primary/secondary drying that deliver low residual moisture without cake melt-back.
Excipients & cake quality. We pick bulking agents and stabilizers that produce elegant, intact cakes with fast, complete reconstitution.
Scale-down/scale-up linkage. We prove that laboratory cycles predict production cycles; we match heat transfer, shelf temperatures, and chamber pressures so execution aligns.
Post-lyo discipline. We control vacuum levels and stopper insertion timing; we measure residual moisture and headspace gases inline where equipment supports it.

Decision rule: we lyophilize when stability or logistics win convincingly; otherwise, we keep the formulation liquid and document why.

Visual inspection & particulates (seeing what matters)

Every container passes through eyes—human, machine, or both. We treat this as a science, not a rite.

Manual & automated inspection. We train with defect libraries and classifier sets; we validate machine sensitivity against real defects and surrogates.
Visible particulates & appearance. We set clear accept/reject criteria and AQL sampling that withstands audit.
Subvisible particulates. For parenterals, we test to route-appropriate expectations; we trend counts and investigate shifts.

Principle: we design processes upstream that make inspection boring.

Container-closure integrity (CCIT)

Integrity isn’t a slogan; it is a measurement plan.

Deterministic methods. We deploy vacuum decay, high-voltage leak detection, and helium mass-spectrometry where justified; we size sampling statistically, not symbolically.
Probabilistic methods. Dye ingress appears in early development when appropriate. We replace it with deterministic approaches as programs mature.
Acceptance criteria. We set numeric thresholds that operators can act on; we link integrity outcomes to stopper, crimp, and processing parameters.

Net effect: you can show, with data, that vials or syringes remained sealed from fill through shipment.

Environmental & personnel controls (where sterility is defended)

Our facilities are designed to keep risk low and predictable.

Classifications. We run ISO-classified rooms (e.g., ISO 5 work zone in isolators with ISO 7/8 background), positive pressure cascades, and unidirectional flows.
Monitoring. We execute continuous non-viable particle monitoring where appropriate and phase-appropriate viable sampling (air and surfaces); we trend excursions and trigger CAPA when needed.
Interventions. We minimize them by design; when unavoidable, we document them and re-qualify impacted zones.
Decontamination. We apply validated decon cycles (e.g., vapor-phase sanitants) with robust biological indicators and residue controls.

People matter: gowning qualification and periodic re-qualification are part of the life of the line.

Analytics & release (drug product truth)

We test what patients and inspectors care about—no more, no less.

Sterility & endotoxin. Phase-appropriate sterility tests and bacterial endotoxins tests; we trend data and investigate anomalies.
DP identity & potency. We bridge to DS assays or deploy DP-specific potency methods; we verify no matrix-induced artifice.
Chemistry. pH, osmolality, assay/concentration, residual solvent (where applicable), and appearance.
Particles. Visible and subvisible particulate testing suitable to presentation.
For lyo. Residual moisture, reconstitution time, cake appearance and structure—recorded, trended, and gated.
For PFS/cartridges. Extractables/leachables strategies scaled to risk; glide force and break-loose characterization aligned to device specs.

Documentation: batch-linked CoAs, method files with qualification/validation status, and trending charts live in the record.

Packaging, labeling & cold chain (getting to clinic intact)

Supply success isn’t a label—it is a lane you can trust.

Secondary packaging. We select cartons and inserts that protect containers and limit shedding; we use tamper-evident closures where required.
Labeling & serialization. We print what regulators and sites require—readable, traceable, and sanity-checked.
Shipping lanes. We validate lanes with thermal profiles that mirror reality and we pick shippers that operators can actually pack.
Time out of refrigeration. We define it from stability data—not wishful thinking; we print it and we train sites to respect it.

Goal: the first patient dose is indistinguishable from the last vial in the last shipper.

Facilities & equipment (selected highlights)

Isolator and RABS lines for vials, PFS, and cartridges, with automated in-process controls (IPC) and recipe-driven changeovers.
Peristaltic and piston dosing options, with gravimetric and volumetric checks; nitrogen overlays when oxidation matters.
Lyophilizers with shelf mapping, vacuum instrumentation, and data capture for primary/secondary drying control; scale-down tools that actually predict.
Inspection systems for machine and manual inspection, supported by validated illumination, rotation, and image capture.
CCIT platforms capable of deterministic testing; sampling and decision logic embedded in SOPs.
Utilities & suites: ISO 7/8 backgrounds, ISO 5 work zones in isolator; validated utilities (HPW/clean steam/compressed air) with trending accessible to QA.
Data systems: validated CDS/LIMS/ELN and eBMR/eBR with audit trails, access controls, and versioning aligned to ALCOA+.

cGMP, regulatory, and QMS (what you’ll feel day-to-day)

Quality by Design. QTPP → CQAs → CPPs documented in protocols and translated into batch recipes.
Digital QMS. Deviation/CAPA, change control, investigations, and training—harmonized across San Diego & Montréal with mirrored methods and release packages.
Regulatory authoring. We write clear DP sections for IND/IMPD/BLA, including filtration feasibility, media fills/process simulations, inspection performance, and CCIT; we answer reviewer questions with statistics plans and raw data.
Audit readiness. We maintain media fill histories, EM trend reports, and AQL outcomes so an audit feels like a well-told story, not a scavenger hunt.

Media fills & process simulation (prove the aseptic claim)

We simulate aseptic operations under worst-case conditions.

Design. We include planned interventions, line speeds, and hold times; we run sufficient replicates to be credible.
Readout. Growth units are counted and mapped; failure modes are documented with CAPA.
Lifecycle. We repeat simulations by schedule and after meaningful changes—then we trend the data.

Outcome: an aseptic program that convinces on paper because it performs in practice.

Program Onboarding (your first 30 days)

Speed is useful only if outputs are inspection-grade. In month one you receive:

A phase-appropriate DP control strategy that maps QTPP → CQAs (sterility, endotoxin, particulates, pH, osmolality, fill accuracy, integrity, residual moisture for lyo) → CPPs (filtration, fill, stoppering, capping, lyo, inspection, CCIT).
A feasibility pack—sterile filtration screens (recovery/integrity), preliminary particulate risk assessment, and for lyo candidates, a scale-down cycle hypothesis with key risks.
A Gantt & risk map (FMEA) with decision gates to IND/registration; plus a draft label/pack/ship plan tied to stability and site needs.

Start: share presentation (vial/PFS/cartridge), dose and route, DS formulation and filterability notes, and stability goals. We return a design space, unit-operation parameters, and a documented path to GMP.

Typical timelines (indicative, product-gated)

Feasibility (2–6 weeks). Filter recovery/integrity, bulk hold studies, initial fill tests, and—for lyo—collapse/eutectic exploration.
Development (2–4 months). DoE for filtration and fill settings; line qualification; lyo cycle development with scale-down predictive confirmation; inspection/CCIT methods ready; label/pack/ship draft.
Engineering runs. End-to-end simulated lots under isolator/RABS; AQL qualification; CCIT sampling; lane validation planning.
Lock. Process description, validated or phase-appropriate qualified methods, batch records, and regulatory text.

We don’t push dates your molecule won’t keep. We show the gates and how to pass them fast—without detours.

Tech transfer & rescue programs

When DP programs arrive frayed, we re-stitch them.

Document triage. Methods, deviations, EM trends, sterility history, AQL failures, CCIT outcomes, and change controls.
Gap map. Which CQAs are unguarded, which CPPs drift, and which fixes buy the most risk reduction first.
Stabilize → optimize → re-lock. We don’t ship risk. We reduce it, document it, and gate it.

ESG & supply chain (because reliability is a quality attribute)

Sane disposables. Closed, single-use fluid paths for asepsis where they reduce risk and setup time; stainless where cleaning validation and cost win.
Qualified alternates. Stoppers, syringes, filters, and shippers with comparability ready; stocking plans matched to campaign risk.
Energy & water awareness. We schedule lyo and utilities to minimize spikes and waste, without compromising sterility or stability.

Deliverables (what you can hold)

DP control strategy tied to patient/regulatory needs.
Filtration feasibility & integrity reports with recovery, ΔP, and temperature windows.
Filling line settings (speed, nozzle, nitrogen, IPC sampling) with validation/qualification outcomes.
Lyophilization dossier (cycle, residual moisture, cake quality, reconstitution).
Inspection & CCIT packages with acceptance criteria, training records, and trending.
Label/pack/ship plan with lane validation and time-out-of-refrigeration guidance.
Batch records (eBMR/eBR) and CMC text ready for submission.

Frequently asked (straight answers)

Is isolator always required? We prefer it when risk justifies; RABS remains an option with strong controls. We’ll show the risk calculus and the EM performance.
Can you fill high-viscosity biologics? Yes—viscosity dictates dosing tech and speeds; we validate accuracy and container integrity at settings we can hold.
Do you support PFS device verification? We coordinate with device partners for break-loose/glide force, needle shield, and lubricant strategies—without pretending DP physics don’t exist.
How do you avoid filter-induced loss? We screen membranes on real bulk, control ΔP/temperature, stage prefilters only when needed, and prove recovery.
Lyo or liquid? If lyo extends shelf life or shipping flexibility meaningfully, we build it. If liquid meets stability and operational truth, we keep it liquid and document why.

Summary—why MycoVista for fill–finish

Because patients don’t receive a process; they receive a dose. We design formulation, filtration, aseptic filling, lyophilization, inspection, integrity, and cold chain as one system. We prove sameness when you change, and we move from Design → Data → Decision with documents and performance that withstand inspection.

MycoVista | San Diego, CA & Montréal, Canada
Start Program Onboarding → Share presentation, route, dose goals, DS details, and stability targets. We’ll return a design space, control strategy, and a documented path to GMP.

EN / FR support available.